PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.01
D/E 50-75% of TRVN's 0.02. Mohnish Pabrai would examine if this balance sheet strength creates strategic opportunities.
6.24
Dangerously higher net debt above 1.5x TRVN's 2.14. Jim Chanos would check for potential debt spiral risks.
-1373.41
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
5.52
Current ratio 50-75% of TRVN's 8.46. Bill Ackman would demand clear path to liquidity improvement.
No Data
No Data available this quarter, please select a different quarter.